YORK: Aptamer Group plc (AIM: APTA), a developer of next-generation synthetic binders for the life science industry, announced Tuesday a new development and licensing agreement with an established global life sciences and diagnostics company, part of a major multinational conglomerate.
Under the agreement, Aptamer will develop a custom Optimer®-Fc reagent for use in immunohistochemistry (IHC) assays and diagnostic kits using its proprietary platform. The partner will fully fund the development, expected to be completed within 12 months, for an undisclosed sum. If successfully validated, the reagent is anticipated to be integrated into commercial IHC kits, with a launch expected this year.
The deal includes a licensing arrangement in which Aptamer will receive a 2% royalty on net sales of kits containing the licensed reagent, subject to minimum royalty commitments. The kits are expected to be distributed through global life sciences research channels.
The partnership highlights Aptamer’s strategy to expand its Optimer platform in high-value markets while securing recurring revenue.
“This collaboration validates the strength of our Optimer platform and provides a clear path to revenue generation,” said CEO Dr. Arron Tolley.
Financial terms and the partner’s identity were not disclosed due to commercial sensitivity. Aptamer said it will provide further updates as needed.